Spark Therapeutics

Roche's digital partnerships flourish under live-and-let-live approach
Roche's digital partnerships flourish under live-and-let-live approach
Fierce Pharma
Roche
digital pharma
Spark Therapeutics
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
Roche's $4.8B deal for Spark cleared by FTC after long delay
Roche's $4.8B deal for Spark cleared by FTC after long delay
Biopharma Dive
Roche
Spark Therapeutics
M&A
FTC
Flag link:
Could Spark Therapeutics’ merger with Roche finally get the go-ahead?
Could Spark Therapeutics’ merger with Roche finally get the go-ahead?
Pharmaforum
Spark Therapeutics
Roche
UK
M&A
CMA
Flag link:
Roche extends tender offer for Spark Therapeutics, again
Roche extends tender offer for Spark Therapeutics, again
Marketwatch
Roche
Spark Therapeutics
M&A
Flag link:
Disruptor of the Year: The Federal Trade Commission
Disruptor of the Year: The Federal Trade Commission
Biopharma Dive
FTC
M&A
Roche
Spark Therapeutics
Flag link:
Put on hold music: Roche delays Spark buyout for the 9th — and quite possibly not the last — time
Put on hold music: Roche delays Spark buyout for the 9th — and quite possibly not the last — time
Endpoints
Roche
M&A
Spark Therapeutics
Flag link:
Why Roche's Acquisition Of Spark May Be Complete By Year's End
Why Roche's Acquisition Of Spark May Be Complete By Year's End
Investors Business Daily
Roche
Spark Therapeutics
M&A
Flag link:
With biosimilar threat under control (for now), Roche savors demand for its new drugs
With biosimilar threat under control (for now), Roche savors demand for its new drugs
Endpoints
Roche
M&A
Spark Therapeutics
China
Flag link:
Roche sets new deadline for Spark acquisition as divestiture speculation brews
Roche sets new deadline for Spark acquisition as divestiture speculation brews
Endpoints
Roche
Spark Therapeutics
M&A
Flag link:
Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already
Roche-Spark deal review in U.K. unnerves M&A watchers—and they were spooked already
Fierce Pharma
M&A
UK
Spark Therapeutics
Roche
antitrust
CMA
Flag link:
UK cost watchdog recommends Novartis' blindness therapy Luxturna
UK cost watchdog recommends Novartis' blindness therapy Luxturna
Yahoo/Reuters
Novartis
gene therapy
Luxturna
UK
NICE
Spark Therapeutics
Flag link:
Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?
Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?
Endpoints
Roche
Spark Therapeutics
FTC
CMA
M&A
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
Yahoo/Benzinga
biotech
earnings
Immunic
Alkermes
Conatus
Aevi Genomic
Tricida
Curis
Ultragenyx
Leap Therapeutics
Cidara Therapeutics
Akcea
Spark Therapeutics
Eli Lilly
AnaptysBio
clinical trials
Flag link:
Roche, Spark push back takeover deadline in $4.3 billion deal
Roche, Spark push back takeover deadline in $4.3 billion deal
Yahoo/Reuters
Roche
Pharma CEOs
Severin Schwan
M&A
Spark Therapeutics
Flag link:
Sangamo backs up early success for hemophilia gene therapy
Sangamo backs up early success for hemophilia gene therapy
Biopharma Dive
Sangamo
gene therapy
hemophilia A
SB-525
Pfizer
Spark Therapeutics
Biomarin
Flag link:
The top 10 most-expensive meds in the U.S.—and they're not the usual suspects
The top 10 most-expensive meds in the U.S.—and they're not the usual suspects
Fierce Pharma
drug pricing
GoodRx
Novartis
Spark Therapeutics
Zolgensma
Luxturna
Flag link:
FTC demands could mean months-long delay for Roche-Spark deal
FTC demands could mean months-long delay for Roche-Spark deal
Biopharma Dive
Roche
Spark Therapeutics
FTC
M&A
Flag link:
Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout
Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout
Endpoints
Spark Therapeutics
Roche
FTC
UK
M&A
Flag link:
What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay
What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay
Endpoints
Roche
Spark Therapeutics
M&A
Flag link:

Pages